NFC
REGN icon

Northeast Financial Consultants’s Regeneron Pharmaceuticals REGN Stock Holding History

Northeast Financial Consultants’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$563K Sell
1,073
-501
-32% -$280K 0.02% 195
2025
Q1 		$998K Sell
1,574
-94
-6% -$64.7K 0.04% 151
2024
Q4 		$1.19M Hold
1,668
– – 0.05% 141
2024
Q3 		$1.75M Buy
1,668
+3
+0.2% +$3.34K 0.08% 111
2024
Q2 		$1.75M Hold
1,665
– – 0.08% 106
2024
Q1 		$1.6M Sell
1,665
-66
-4% -$62.8K 0.08% 114
2023
Q4 		$1.52M Hold
1,731
– – 0.08% 114
2023
Q3 		$1.42M Hold
1,731
– – 0.09% 117
2023
Q2 		$1.24M Hold
1,731
– – 0.08% 123
2023
Q1 		$1.42M Hold
1,731
– – 0.09% 116
2022
Q4 		$1.25M Sell
1,731
-112
-6% -$82.6K 0.08% 123
2022
Q3 		$1.27M Hold
1,843
– – 0.09% 116
2022
Q2 		$1.09M Sell
1,843
-100
-5% -$65K 0.08% 132
2022
Q1 		$1.36M Buy
1,943
+100
+5% +$63.3K 0.08% 132
2021
Q4 		$1.16M Hold
1,843
– – 0.07% 146
2021
Q3 		$1.11M Sell
1,843
-40
-2% -$24.8K 0.07% 148
2021
Q2 		$1.05M Hold
1,883
– – 0.07% 153
2021
Q1 		$891K Buy
1,883
+540
+40% +$263K 0.07% 152
2020
Q4 		$649K Sell
1,343
-40
-3% -$21.6K 0.05% 167
2020
Q3 		$774K Sell
1,383
-134
-9% -$81.2K 0.07% 142
2020
Q2 		$945K Buy
1,517
+20
+1% +$11.4K 0.09% 129
2020
Q1 		$731K Buy
1,497
+310
+26% +$128K 0.08% 144
2019
Q4 		$446K Sell
1,187
-15
-1% -$5.05K 0.04% 192
2019
Q3 		$333K Sell
1,202
-15
-1% -$4.44K 0.03% 221
2019
Q2 		$381K Buy
1,217
+50
+4% +$16.6K 0.04% 202
2019
Q1 		$479K Buy
+1,167
New +$481K 0.05% 180

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northeast Financial Consultants's REGN Position: Q2 2025 in Review

Northeast Financial Consultants reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2025, selling an estimated $280K and leaving 1,073 shares worth $563K. The position accounts for 0.02% of the portfolio, ranked #195.

Northeast Financial Consultants first reported a position in REGN in Q1 2019 and has held it in 26 quarters since. The position peaked at $1.75M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Northeast Financial Consultants held 1,073 shares of Regeneron Pharmaceuticals worth $563K as of Q2 2025.
  • Northeast Financial Consultants sold 501 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $280K.
  • Regeneron Pharmaceuticals made up 0.02% of Northeast Financial Consultants's portfolio in Q2 2025, its #195 holding.
  • Northeast Financial Consultants first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Northeast Financial Consultants's Regeneron Pharmaceuticals position peaked at $1.75M in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.